Atossa Therapeutics, Inc. Sees Notable Reduction in Short Interest

Atossa Therapeutics, Inc. (NASDAQ:ATOS) experienced a significant decline in short interest during December. By December 15th, the total short interest amounted to 8,200,000 shares, representing a decrease of 29.3% compared to the 11,600,000 shares reported on November 30th. With an average daily trading volume of 705,500 shares, the current short-interest ratio stands at 11.6 days.

Analysts Have Positive Outlook

Equity analysts have recently shared their evaluations of Atossa Therapeutics' stock. HC Wainwright maintained a "buy" rating, establishing a target price of $7.00 in a report dated December 12th. Additionally, Ascendiant Capital Markets raised their target price for Atossa's shares from $6.50 to $7.00, also issuing a "buy" rating on December 9th. However, it is worth noting that StockNews.com downgraded Atossa Therapeutics from a "hold" to a "sell" rating in a research note on November 18th.

Current Stock Performance

As of Friday, Atossa Therapeutics' shares opened at $0.98. The company has a market capitalization of $123.42 million, with a price-to-earnings ratio of -4.46 and a beta of 1.21. The stock has reached a low of $0.77 and a high of $2.31 within the last year. The 50-day and 200-day simple moving averages for the stock are $1.27 and $1.31, respectively.

Institutional Investment Trends

Recently, several institutional investors have altered their holdings of Atossa Therapeutics. XTX Topco Ltd acquired a new stake during the second quarter, valued at around $29,000. Intech Investment Management LLC also purchased a new position in the third quarter, worth about $29,000. SG Americas Securities LLC increased its stake in Atossa by 254.3% during the same quarter, now holding 41,849 shares valued at $64,000 after an additional purchase of 30,037 shares. The Manufacturers Life Insurance Company acquired a new stake valued at approximately $75,000, while Rhumbline Advisers bought a new position worth about $161,000 in the second quarter. Institutional investors currently own 12.74% of the stock.

Company Overview

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments addressing unmet medical needs in oncology, particularly for women with breast cancer and other conditions within the United States. Its lead drug candidate is (Z)-endoxifen, an oral active metabolite of tamoxifen, which is currently undergoing Phase II clinical trials aimed at treating and preventing breast cancer.

Stay Informed

This article serves as a summary of recent trends regarding Atossa Therapeutics and its market performance.

Atossa, stocks, investment